Caribou Biosciences Stock News

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Hau

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurw

Caribou Biosciences, Inc. (NASDAQ:CRBU) insider Barbara G. Mcclung purchased 6,127 shares of the businesss stock in a transaction that occurred on Tuesday, December 7th. The shares were purchased at an average cost of $2.69 per share, with a total value of $16,481.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, []

In last trading session, Caribou Biosciences Inc. (NASDAQ:CRBU) saw 0.31 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $17.07 trading at -$0.94 or -5.22% at ring of the bell on the day assigns it a market valuation of $997.57M. That closing price of CRBUs stock is Caribou Biosciences Inc. (NASDAQ:CRBU) -3.45% Down Over Last Week, What Happens Next? Read More »

HC Wainwright began coverage on shares of Caribou Biosciences (NASDAQ:CRBU) in a research report sent to investors on Tuesday, Price Targets.com reports. The firm issued a buy rating and a $28.00 price target on the stock. A number of other analysts have also weighed in on the company. Citigroup upgraded Caribou Biosciences from a neutral [] The post HC Wainwright Initiates Coverage on Caribou Biosciences (NASDAQ:CRBU) appeared first on ETF Daily News .

Caribou Biosciences, Inc. (NASDAQ:CRBU) Oppenheimer issued their FY2021 earnings per share estimates for Caribou Biosciences in a research note issued on Tuesday, November 30th. Oppenheimer analyst M. Breidenbach expects that the company will post earnings of ($1.88) per share for the year. Oppenheimer currently has a Outperform rating and a $36.00 price target on [] The post Caribou Biosciences, Inc. Forecasted to Earn FY2021 Earnings of ($1.88) Per Share (NASDAQ:CRBU) appeared first on ETF Daily News .

Caribou Biosciences, Inc. (NASDAQ:CRBU) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 1,540,000 shares, a growth of 32.8% from the October 31st total of 1,160,000 shares. Based on an average daily trading volume, of 577,300 shares, the days-to-cover ratio is presently 2.7 []

Caribou Biosciences, Inc. (NASDAQ:CRBU) fell 4.5% during trading on Wednesday . The stock traded as low as $17.44 and last traded at $17.75. 6,853 shares changed hands during trading, a decline of 99% from the average session volume of 671,374 shares. The stock had previously closed at $18.59. Several research firms recently commented on CRBU. []

Equities researchers at Oppenheimer started coverage on shares of Caribou Biosciences (NASDAQ:CRBU) in a research report issued on Tuesday, The Fly reports. The brokerage set an outperform rating on the stock. CRBU has been the topic of a number of other reports. SVB Leerink initiated coverage on Caribou Biosciences in a research note on Tuesday, []

The shares of Caribou Biosciences Inc (NASDAQ: CRBU) have received a $28 price target from H.C. Wainwright.

Equities research analysts at HC Wainwright assumed coverage on shares of Caribou Biosciences (NASDAQ:CRBU) in a research report issued on Tuesday, The Fly reports. The firm set a buy rating on the stock. A number of other research firms have also commented on CRBU. SVB Leerink started coverage on shares of Caribou Biosciences in a []

Caribou Biosciences Inc. (NASDAQ:CRBU) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 0.45% to the previous days close as strong demand from buyers drove the stock to $17.68. Actively observing the price movement in the last trading, the stock closed the session at $17.60, falling within a range of $16.99 Caribou Biosciences Inc. (NASDAQ: CRBU) Is An Exciting Stock To Watch. Read More »

BERKELEY, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Hau

BERKELEY, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurw

Related Stocks: CRBU , OMGA ,